Standard Biotools INC Form 4 insider transactions

Casdin Partners files an amended Form 4 to update beneficial ownership information in Standard BioTools Inc. (LAB), indicating continued director and 10% ownership status.

Director Thomas D. Carey acquired shares in Standard BioTools Inc. through restricted stock units (RSUs) in lieu of cash compensation.

Director Troy Cox acquired 62,910 shares of Standard BioTools Inc. through Restricted Stock Units (RSUs) in lieu of cash compensation.

Michael Egholm, President & CEO of Standard BioTools Inc., sold 31,031 shares of common stock to cover tax obligations arising from the vesting of restricted stock units.

Standard BioTools CEO, Michael Egholm, sold 28,795 shares to cover tax obligations arising from the vesting of restricted stock units.

Jeffrey G. Black, SVP & Chief Financial Officer of Standard BioTools Inc., sold 6,690 shares of common stock on August 20, 2024, to cover tax obligations arising from vesting restricted stock units.

CEO Michael Egholm sold shares of Standard BioTools to cover tax obligations arising from the vesting of restricted stock units.

Casdin Partners Master Fund, L.P. reports purchasing 250,000 shares of Standard BioTools Inc. at a weighted average price of $2.187 per share, increasing their total holdings.

Casdin Partners and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases between August 22 and August 26, 2024.

Casdin Partners and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases, as disclosed in a recent SEC Form 4 filing.

Jeffrey G. Black, SVP & CFO of Standard BioTools Inc., reports the vesting and subsequent tax withholding of shares related to restricted stock units, as well as the forfeiture of unvested RSUs due to his upcoming resignation.

Casdin Partners Master Fund, L.P. reports the acquisition of 1,200,000 shares of Standard BioTools Inc. common stock at a weighted average price of $1.5946, while addressing potential short-swing profit liabilities.

Casdin Partners and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases, while also addressing potential short-swing profit liabilities.

Casdin Partners and related entities have increased their holdings in Standard BioTools Inc. through recent purchases of common stock.

Casdin Partners and related entities report acquiring additional shares of Standard Biotools Inc., while also addressing potential short-swing profit liabilities.

Eli Casdin, a director and 10% owner of Standard BioTools Inc., reports acquiring 1,588 shares of common stock through Restricted Stock Units (RSUs) in lieu of cash compensation.

Director Frank Witney reports acquisition of shares and options in Standard Biotools Inc.

Director Troy Cox reports acquisition of restricted stock units and stock options, as well as forfeiture of previously granted RSUs, in Standard BioTools Inc.

Eli Casdin, a director and 10% owner of Standard BioTools Inc., reported acquiring shares and options, along with adjustments to existing holdings through various funds.

Director Fenel M. Eloi reports acquisition of stock options and restricted stock units in Standard BioTools Inc.

Director Thomas D. Carey of Standard BioTools Inc. received stock options and restricted stock units (RSUs) while forfeiting previously granted RSUs related to the proposed merger with SomaLogic.

Director Kathy Hibbs reports acquiring and disposing of Standard BioTools Inc. securities, including restricted stock units and stock options.

Casdin Partners executed a series of cross-trades involving Standard BioTools Inc. common stock, resulting in adjustments to the holdings of various Casdin-affiliated funds and entities.

Casdin Partners, a significant shareholder in Standard BioTools Inc., has increased its position through a recent purchase of 100,000 shares at $2.60 per share.

Casdin Partners and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases between May 20-22, 2024.

Michael Egholm, CEO of Standard BioTools Inc., was granted 1,000,000 Restricted Stock Units (RSUs) and options to purchase 2,250,000 shares of common stock on May 20, 2024.

Jeffrey G. Black, SVP & Chief Financial Officer of Standard BioTools Inc., reports acquisition of shares and options.

Hanjoon Alex Kim, Chief Operating Officer of Standard Biotools Inc., reports acquisition of shares and options in the company.

Casdin Partners Master Fund, L.P. and related entities have increased their holdings in Standard BioTools Inc. (LAB) through a series of open market purchases between May 15 and May 17, 2024.

Jeffrey G. Black, SVP & Chief Financial Officer of Standard BioTools Inc., reports the vesting of restricted stock units and subsequent stock transactions.